Comparative bioavailability of two losartan formulations in healthy human volunteers after a single dose administration

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 3, 2006, Pages 142-148

  Oliveira, C H ^a   Medeiros Silva, R ^a   Santagada, V ^c   Caliendo, G ^c   Perissutti, E ^c   Prado Galuppo, M ^a   Marcondes Rezende, V ^a   Barrientos Astigarraga, R E ^a   Duarte Mendes, G ^a,b   De Nucci, G ^a,b,d  

^a Cartesius Development of Clinical Research   (Italy)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d NONE   (Brazil)

Author keywords

Bioequivalence; LC MS MS; Mass spectrometry; Valsartan

Indexed keywords

DRUG METABOLITE; LOSARTAN; LOSARTAN POTASSIUM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STRUCTURE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN EXPERIMENT; ION MONITORING; MALE; NEGATIVE ION ELECTROSPRAY; NORMAL HUMAN; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; UNITED STATES; VOLUNTEER;

EID: 33644778521     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44142     Document Type: Article

References (9)

1. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001; 103: 904-912.
2. Farthing D, Sica D, Fakhry I, Pedro A, Gehr TW. Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate. J Chromatogr B Biomed Sci Appl. 1997; 704: 374-378.
3. Food and Drug Administration. Bioavailability and bioequivalence requirements; abbreviated applications; proposed revisions - FDA. Proposed rule. Fed Regist. 1998; 63: 64222-64228.
4. Iwasa T, Takano T, Hara K, Kamei T. Method for the simultaneous determination of losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 1999; 734: 325-330.
5. Moraes MO, Lerner FE, Corso G, Bezerra FA, Moraes ME, De Nucci G. Fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry. J Clin Pharmacol. 1999; 39: 1053-1061.
6. Polinko M, Riffel K, Song H, LO MW. Simultaneous determination of losartan and EXP 3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal. 2003; 33: 73-84.
7. Sifton DW (ed). Physicians' Desk Reference Medical Economics. 55th edition. Stamford, CT: Thomson Healthcare; 2001. pp. 1668-1670.
8. 1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats. J Pharm Biomed Anal. 1998; 16: 863-873.
9. Yeung PK, Jamieson A, Smith GJ, Fice D, Pollak PT. Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection. Int J Pharm. 2000; 204: 17-22.